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ABSTRACT 
Becent studies have suggested that maternal TSH receptor-blocking 
antibodies might be of primary etiological importance in some cases of 
transient congenital hypothyroidism (CH). Because these antibodies 
are extremely potent, we evaluated the feasibility of identifying babies 
at risk by using readily available newborn blood spots. Blood spots 
obtained from 84 normal babies (group 1) and from 354 infants whose 
initial T, was less than the tenth percentile for the assay and whose 
TSH was 40 mU/L or more (group 2) were studied without knowledge 
of the diagnosis. Blood was eluted from spots overnight and evaluated 
for [‘161]TSH binding inhibition (TBI) to solubilized porcine thyroid 
membranes. Four spots obtained from 3 group 2 babies, but none of 
those from the group 1 infants, exhibited TBI activity greater than 3 
SD above the normal mean (33.9%). Four additional hypothyroxinemic 
infants whose mothers had Graves’ disease were also negative. Subse- 
quent follow-up revealed that all 3 positive babies had transient CH, 
and all 3 mothers had primary myxedema. Potent TBI activity was 
confirmed in the serum of all 3 mothers and in the 2 babies in whom 
it was evaluated at birth. 
We conclude that newborn blood spots can be used to detect potent 
maternal TBI activity, and that this identifies a baby likely to have 
transient, rather than permanent, CH. Because of their stability and 
ease of collection and handling, newborn blood spots should offer a 
convenient tool for future studies aimed at defining in more detail the 
incidence and clinical characteristics of this unique syndrome. (J Clin 
Endocrinol Metab 77: 1005-1008,1993) 
A SYNDROME of transient congenital hypothyroidism (CH) has been described in babies born to mothers 
with autoimmune thyroid disease and potent TSH receptor- 
blocking antibodies in serum (l-3). Infants with this disorder 
are indistinguishable at birth from those with thyroid dys- 
genesis, because they frequently have severe hypothyroid- 
ism, no goiter is palpable either in the baby or mother, and 
thyroid uptake is significantly reduced or absent (4,5). Unlike 
sporadic thyroid dysgenesis, however, babies with blocking 
antibody-induced CH tend to have transient disease, and the 
disorder has a high recurrence rate in subsequent offspring 
due to the tendency of these antibodies to remain elevated 
for a long time in maternal serum (l-5). 
The prevalence of TSH receptor-blocking antibodies as a 
cause of CH is unknown. Because only those babies born to 
mothers with the most potent blocking antibodies develop 
hypothyroidism (3, 6-8) and the binding inhibitory effect 
correlates well with inhibition of TSH-induced stimulation 
of thyroid growth and function (6, 9, lo), we hypothesized 
that it might be possible to screen for TSH receptor-blocking 
antibodies by evaluating TSH binding inhibition (TBI) using 
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readily available newborn blood spots. The present studies 
were performed to evaluate the feasibility of this method. 
Materials and Methods 
Study populuti4m 
Serum was initially obtained from two patients with known primary 
myxedema (1”M) and two normal individuals for use in the pilot studies 
to be described. Patient 1 has had two babies with transient CH, and 
her innnunoglobulin G (IgG) results have been previously reported (10). 
Patient 2 was a IO-yr-old girl who presented with severe 1”M and was 
known to have TSH biding inhibitory IgG of intermediate potency. 
Blood spots were obtained from the New York State Hypothyroid 
Screening Program between 1987 and 1988 and included 84 blood spots 
from normal babies (group 1) as well as 465 samples from 354 infants 
whose initial T4 was less than the tenth percentile for the assay and 
whose TSH was greater than or equal to 40 mU/L (group 2). Of the 
group 2 babies, 150 were considered to have confiied CH because 
their TSH levels had remained elevated on retesting. In the remaining 
204 unconfirmed babies, thyroid function tests were normal on repeat 
exam. This miscellaneous patient group included babies with borderline 
values and those who had been screened before 4 days of age because 
of early discharge. As an additional control, 4 spots obtained from 
hypothyroxinemic infants whose mothers had Graves’ disease were 
studied as well. All spots had been stored desiccated at -4 C and were 
studied without knowledge of the diagnosis. 
The study protocol was approved by the Committee on the Protection 
of Human Subjects in Research at the University of Massachusetts 
Medical Center. 
Methods 
In the initial studies, dried blood spots were prepared by mixing 
washed cells from normal henarinixed blood with serum containine the 
desired test hormone or IgG h a ratio of l:l, spotting the mixture~nto 
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filter paper, and allowing the blood to dry for at least 18 h. Disks were 
punched using a standard l/Bth-in. paper punch and incubated in 200 
PL 50% Coon’s Modified Ham’s F-12 culture medium overnight at 4 C. 
Fifty microliters of eluted blood were then assayed for [?]bovine TSH 
@TSH) binding inhibitory (TBI) activity according to the method of 
Southgate et al. (11). Each sample was studied in duplicate. The assay 
used Triton X-lOO-solubilized porcine thyroid membranes and receptor- 
purified bTSH, kindly supplied by Dr. John Pierce, University of Cali- 
fornia-Los Angeles, as tracer. In a few of the preliminary studies, a 
commercial kit (Kalibre TSH Receptor Antibody, Kronus, Dana 
Point, CA) was used. Both methods gave equivalent results. Human 
pituitary TSH (NIDDK hTSH-I-6) was provided by the National Hor- 
mone and Pituitary Program; recombinant human TSH (Genzyme) was 
the gift from Dr. Lewis Braverman. 
Results were corrected for nonsaturable binding, and the percent 
inhibition of [?]bTSH binding was ex 
P 
ressed as a TBI index, computed 
as follows: 1 - (specific binding of [’ ‘IJbTSH in the presence of test 
sample/specific binding of [1251]bTSH in presence of control samples) X 
100; unknowns were compared with the mean value of 6-10 normal 
spots evaluated in the same assay. 
All spots were studied in duplicate. Any spot with a result 1.75 SD 
greater than the normal mean or higher was repeated. 
Results 
Pilot studies 
Initial studies demonstrated that the TBI activity of blood 
spots obtained from the two 1”M patients whose IgG was 
known to have strong and intermediate potency, respec- 
tively, could be clearly distinguished from normal, and that 
the previously identified relative difference in potency could 
be demonstrated (Fig. 1). A dose-response curve was ob- 
served; potency was dependent on the number of filter paper 
disks used for elution. From these results, elution of four 
blood spot disks was selected for routine assay, as TBI activity 
was readily detectable with this quantity of blood and this 
amount of blood was obtainable from the majority of spots. 
Initial studies indicated that elution with either 50% Coon’s 
F-12 or 10 mmol/L Tris-50 mmol/L NaCl gave equivalent 
results, and both were superior to 20% sucrose. Elution with 
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FIG. 1. Inhibition of [1261]TSH binding by two patients with primary 
myxedema (0) and two control individuals (0). Results with eluted 
blood mirrored known TBI activity in serum and were dose dependent; 
inhibition was dependent on the number of spots eluted. 
2 mol/L NaCl completely blocked [‘251]bTSH binding of both 
normal and 1”M samples (results not shown). For the studies 
to be described, 50% Coon’s F-12 medium was used. 
Because the infants to be studied were expected to be 
hypothyroid, experiments were performed to evaluate the 
possible cross-reactivity of human TSH in this heterologous 
RRA. In three separate experiments, 1 U/L human pituitary 
TSH added to serum produced only 17.6 f 7.7% (mean + 
SEM) inhibition of [‘251]bTSH binding. Results with recombi- 
nant hTSH were similar and are shown in Fig. 2. When 
added to blood, spotted onto filter paper, and eluted, as 
much as 2 U/L hTSH, the highest concentration tested, did 
not produce significant inhibition of tracer binding. 
TBI activity in blood spots 
The TBI activity of 84 blood spots obtained from 84 normal 
babies (group 1) and 465 blood spots obtained from 354 
infants with either confirmed (n = 150) or unconfirmed (n = 
204) CH (group 2) was studied (Fig. 3). The mean blood spot 
TBI activity in normal babies was 0.9 f 11.0% (mean f SD). 
Four spots obtained from 3 group 2 babies had TBI activity 
greater than 3 SD above the normal mean (61.4%, 71.9%, 
41.7%, and 54%, respectively) and remained positive on 
retesting (60.2%, 40.9%, 48.1%, and 5&O%, respectively). 
All 3 babies had confirmed CH. Two other normal spots and 
8 other CH spots had activity greater than 2 SD above the 
normal mean on initial testing, but these results were not 
confirmed. No borderline spots, defined as 1.75-2.0 SD 
greater than the mean, were positive on retesting. The inter- 
assay coefficient of variation of a positive control (patient 1) 
studied in 8 assays was 26.7%; the intrassay coefficient of 
variation of this sample was 12.0%. 
As thyroid-stimulating antibodies in patients with Graves’ 
disease could conceivably inhibit TSH binding and be de- 
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FIG. 2. [1261]TSH binding in the presence of increasing amounts of 
unlabeled recombinant hTSH in serum. hTSH in amounts UD to 1000 
mU/L resulted in only slight inhibition of [9]TSH bin&g. When 
added to blood and eluted from spots, as much as 2000 mu/L, the 
highest concentration tested, was similarly without a significant effect. 
Equivalent results were obtained with a purified pituitary TSH prep- 
aration (NIDDK hTSH-l-8). 
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FIG. 3. TBI activity in 84 blood spots from 64 normal babies (group 1) 
and 465 spots from 354 infants whose initial T, was in the lowest tenth 
percentile for the assay and whose TSH was 40 mU/L or more (group 
2). Four spots (*) obtained from 3 group 2 babies, but none from group 
1 infants, exhibited TBI activity greater than 3 SD above the normal 
mean. Four hypothyroxinemic babies of mothers with Graves’ disease 
were also studied and were negative (data not shown). 
TABLE 1. Clinical and laboratory data of three infants with 
significant TBI-positive activity in blood spots and in their mothers 
Infant Mother 
spot 
IlO. Clinical course zezJf Diagnosis %TBII/TRAh (serum) 
157 Transient CH 89.1 1”M 85.5/- 
394 Transient CH 82.8 1”M 77.4/- 
(S/P Graves’) 
320 Transient CH ND 1”M --/382 U/L 
TBII, TSH binding inhibitory Ig, determined at Nicholls Institute 
(San Juan Capistrano, CA; normal value, <lo%). TRAb, TSH receptor 
antibody; this assay, similar to the TBII assay, is based on the method 
of Southgate et al. (11) (normal value, <lO U/L) and was performed 
using a commercial kit (Kalibre, Kronus). ND, Not done. 
tected in the assay, four blood spots from hypothyroxinemic 
babies born to mothers with Graves’ disease were evaluated 
as well. No significant TBI activity was observed. 
Confirmatory studies 
Clinical and laboratory data concerning the three TBI- 
positive babies and their mothers, obtained subsequently, 
are shown in Table 1. All babies had transient CH, and TSH 
binding inhibitory activity in serum was confirmed in the 
two in whom it was tested at birth. All three mothers had 
l”M, and potent TBI activity was present in serum. In one of 
the mothers, hypothyroidism was preceded by severe 
Graves’ disease treated with radioactive iodine. It is of inter- 
est that antimicrosomal [thyroid peroxidase (TPO)] antibodies 
were positive in two of the three mothers and negative in 
the third (data not shown). 
Discussion 
The presence of potent TSH receptor-blocking antibodies 
was confirmed in the serum of all three mothers and in the 
two babies evaluated at birth. Similar to previously reported 
cases, all three mothers had 1”M; in one patient, hypothy- 
roidism was preceded by radioactive iodine therapy for se- 
vere Graves’ disease. It is of interest that TPO antibodies, 
commonly used as a marker of autoimmune thyroid disease, 
were present in just two of the three mothers identified. This 
is consistent with previous reports suggesting that measure- 
ment of TPO antibodies is not an adequate screen for the 
prediction of transient CH (10). 
Although the possibility of a maternal thyrocytotxic factor Because bioactivity was not evaluated specifically, screen- 
responsible for some cases of CH was suggested by Blizzard ing for TBI activity could conceivably have identified babies 
et al. as early as 1960 (12), it was not until 1980 that Matsuura 
et al. (1) first described two babies with transient nongoitrous 
CH born to a mother with 1”M and demonstrated an IgG in 
maternal serum that inhibited TSH binding and TSH-in- 
duced stimulation of thyroid membrane adenyl cyclase. Since 
that time, numerous such cases have been described, and 
strong evidence has been gathered to confirm that the thy- 
rocytotoxic factor in these patients is an antibody to the TSH 
receptor. For example, the blocking activity inhibits TSH 
binding to both the native porcine (4, 10) and human (1, 2, 
6) TSH receptor as well as to the recombinant human (13, 
14) and murine (15) ones. It interferes only with stimulation 
by TSH (2, 3, 6) or the thyroid-stimulating IgGs of Graves’ 
disease patients (9, 16), but not with that induced by post- 
receptor processes (9, 17), except in rare instances (18). The 
blocking activity is associated with the IgG fraction of serum, 
because it can be absorbed by and eluted from staphylococcal 
protein-A affinity columns that specifically bind subclasses 
1, 2, and 4 of IgG (10, 17). An etiological role is suggested 
by the relationship between the severity of the neonatal 
disease and the potency of the in vitro thyroid-blocking 
activity (3) and by the tendency for the neonatal hypothy- 
roidism to parallel the disappearance of maternal IgG from 
the baby’s serum (2). 
We took advantage of previous studies demonstrating that, 
analagous to neonatal hyperthyroid&m in infants of mothers 
with Graves’ disease (19), only babies born to mothers with 
the most potent TSH receptor-blocking activity become hy- 
pothyroid. As 1.5 PL serum were eluted from each of four 
1/8th-in. disks (20), and a volume of 200 PL buffer was used 
for elution, the actual dilution being tested in the present 
study was 4 X 1.5:200 or 1:33. Our findings, thus, correlate 
remarkably well with those of previous studies, which dem- 
onstrated that half-maximal TBI activity in babies of 1”M 
mothers who became hypothyroid was obtained with a 1:30 
to 1:50 dilution of serum. Four spots obtained from three 
babies exhibited the most potent (>3 SD) blocking activity, 
and all three babies had transient hypothyroidism. All were 
in the confirmed CH group; in contrast, no spots in the 84 
normal subjects or 204 unconfirmed CH babies exhibited TBI 
activity of this magnitude. Preliminary studies indicated that 
a serum concentration of hTSH such as might occur in a 
baby with CH did not interfere significantly with [‘251]bTSH 
binding, and that results using eluted blood from blood spots 
were dose dependent and mirrored results using serum. 
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of mothers with Graves’ disease and high titers of thyroid- 
stimulating antibodies or even those with a mixture of TSH 
receptor antibodies of varying bioactivity (21). For this rea- 
son, spots obtained from four known hypothyroxinemic 
infants of Graves’ disease mothers were studied as well; 
none contained significant TBI activity. These results suggest 
that the hypothyroxinemia observed in such babies, there- 
fore, is more likely to be due to maternal thiouracil therapy 
(22). It is of interest that studies from several laboratories 
have demonstrated that stimulating antibodies do not inhibit 
as well as blocking antibodies (8, 13), probably because they 
interact at a different domain on the receptor (14, 15). 
We conclude that newborn blood spots can be used to 
detect potent maternal TBI activity, and that this identifies a 
baby likely to have transient, rather than permanent, hypo- 
thyroidism. Because of their stability and the ease of collec- 
tion and handling, newborn blood spots should offer a 
convenient tool for future studies aimed at defining in more 
detail the incidence and clinical characteristics of this unique 
syndrome. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
Acknowledgments 15. 
Drs. Robert Klein and Marvin Mitchell, New England Congenital 
Hypothyroidism Collaborative, provided the blood spots from two of 
the hypothyroxinemic babies born to mothers with Graves’ disease. 
16. 
References 
1. Matsuura N, Yamada Y, Nohara Y, et al. 1980 Familial neonatal 
transient hypothyroidism due to maternal TSH-binding inhibitor 
immunoglobulins. N Engl J Med. 303:738-741. 
2. Isekl M, Shlmlzu M, Oikawa T, et al. 1983 Sequential serum 
measurements of thyrotropin binding inhibitor immunoglobulin G 
in transient familial neonatal hypothyroidism. J Clin Endocrinol 
Metab. 57~384-387. 
3. Konlshi J, Iida Y, Kasagl K, et al. 1985 Primary myxedema with 
thyrotropin-binding inhibitor immunoglobulins. Ann Intern Med. 
103:26-31. 
4. Connors MH, Styne DM. 1986 Transient neonatal ‘athyreosis’ 
resulting from thyrotropin-binding inhibitory immunoglobulins. Pe- 
diatrics. 78:287-290. 
5. Francis G, Rlley W. 1987 Congenital familial transient hypothy- 
roidism secondary to transplacental thyrotropin-blocking autoanti- 
bodies. Am J Dis Child. 141:1081-1083. 
6. Arlkawa K, Ichikawa Y, Yoshida T, et al. 1985 Blocking type 
antithyrotropin receptor antibody in patients with nongoitrous hy- 
pothyroidism: its incidence and characteristics of action. J Clin 
Endocrinol Metab. 60:953-959. 
7. Inomata H, Sasaki N, Tamaru K, Ushiku H, Nilmi H, Nakajima 
H. 1986 Relationship between potency of blocking type thyrotropin- 
binding inhibitor immunoglobulin in three women with primary 
17. 
18. 
19. 
20. 
21. 
22. 
myxedema and thyroid function of their neonates. Endocrinol Jpn. 
33:353-359. 
Matsuura N, Konishi J, Harada S, et al. 1989 The prediction of 
thyroid function in infants born to mothers with chronic thyroid&. 
Endocrinol Jpn. 36:865-871. 
Iida Y, Konlshi J, KasaRI K, et al. 1987 Inhibition of thvrotrooin- 
induced growth of rat thyroid cells, FRTL-5, by immunoglobulm G 
from patients with primary myxedema. J Clin Endocrinol Metab. 
64:124-130. 
Brown RS, Keating P, Mitchell E. 1990 Maternal thyroid-blocking 
immunoglobulins in congenital hvuothvroidism. 1 Clin Endocrinol 
Metab. 7%:1341-1346. v *- . . 
Southgate K, Creagh F, Teece M, Kingswood C, Smith BR. 1984 
A receptor assay for the measurement of TSH receptor antibodies 
in unextracted serum. Clin Endocrinol (Oxf). 20:539-543. 
Blizzard RM, Chandler RW, Landing BH, Pettit MD, West CD. 
1960 Maternal autoimmunization to thyroid as a probable cause of 
athyrotic cretinism. N Engl J Med. 263:327-336. 
Libert F, Lefort A, Gerard C, et al. 1989 Clonine, seouencina, and 
expression of the human thyrotropin (TSH) recsptok evideke of 
binding of autoantibodies. Biochem Biophys Res Commun. 
165:1250-1255. 
Nagayama Y, Wadsworth HL, Russo D, Chazenbalk GD, Rapo- 
port B. 1991 Binding domains of stimulatorv and inhibitor thvrotro- 
pin (TSH) receptor autoantibodies determined with chimeric TSH- 
lutropin/chorionic gonadotropin receptors. J Clin Invest. 88:336- 
340. 
Kosugl S, Ban T, Akamlzu T, Kohn LD. 1991 Further character- 
ization of a high affinity thyrotropin binding site on the rat thyro- 
tropin receptor which is an epitome for blocking antibodies from 
idiopathic &edema patients but not thyroid stimulating antibodies 
from Graves’ patients. Biochem Biouhvs Res Commun. 180:1118- 
1124. - 
1 I 
Cho BY, Shong YK, Lee HK, Koh C-S, Min HR. 1989 Inhibition 
of thyrotropin-stimulated adenylate cyclase activation, growth of 
rat thyroid cells FRTL-5, by immunoglobulin G from patients with 
primary myxedema: comparison with activities of thyrotropin-bind- 
ing inhibitor immunoglobulins. Acta Endocrinol (Copenh). 120:99- 
106. 
KraIem Z, Lahat N, Glaser B, Baron E, Sadeh 0, Sheinfeld M. 
1987 Thyrotrophin receptor blocking antibodies: incidence charac- 
terization and in-vitro svnthesis. Clin Endocrinol fOxf). 27409-421. 
Takasu N, Mori T, Koizumi Y, Takeuchi S, ‘Yarnada T. 1984 
Transient neonatal hypothyroidism due to maternal immunoglob- 
ulins that inhibit thyrotropin-binding and post-receptor processes. J 
Clin Endocrinol Metab. 59:142-146. 
Zakariia M, McKenzie JM. 1983 Preanancv-associated chances in 
the thyroid-stimulating antibody of Graves’ disease and the”rela- 
tionshiu to neonatal hwerthvroidism. J Clin Endocrinol Metab. 
57:1036-1040. -- ’ 
National Committee for Clinical Laboratory Standards. 1985 
Blood collection on filter paper for neonatal screening programs; 
tentative standard. NCCLS nubkation LA4-T. Villanova: NCCLS: 
pp 163-182. 
1 
Zakarija M, McKenzie JM, Hoffman WH. 1986 Prediction and 
theraov of intrauterine and late-onset neonatal hvuerthvroidism. 1 
Clin &do&no1 Metab. 62:368-371. 
d. , 
Cheron RG, Kaolan MM, Larsen PR. Selenkow HA, Crlzler Ir IF. 
1981 Neonatal Thyroid function after propylthiouracil th&api ior 
maternal Graves’ disease. N Engl J Med. 304:525-528. 
